Jennifer Woyach, MD, Discusses BRUIN CLL-322 Design, Enrollment Process

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, speaks about the BRUIN CLL-322 study.

The phase III open-label randomized study will evaluate fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

It is currently enrolling patients who have previously received a Bruton’s tyrosine kinase inhibitor.

“I think it’s a really excellent trial,” Dr. Woyach said.

Dr. Woyach and colleagues presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Meeting.